PillRx only · Kit · Intra-Articular
Triamcinolone Acetonide Extended-Release Injectable Suspension
Brands: Zilretta
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
2.9K
Rx · 2026 Q1
4.1K
Units dispensed
-1%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Pacira Pharmaceuticals, Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jun 12, 2024RECALLRecall (Class II): Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: P…
Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿C — Recalling firm: PACIRA PHARMACEUTICALS INC — US Nationwide.
- May 7, 2024RECALLRecall (Class II): Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, M…
Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C. — Recalling firm: PACIRA PHARMACEUTICALS INC — U.S. Nationwide.